Neurogene (NGNE) CFO sells 4,800 shares and retains 84,040 including RSUs
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Neurogene Inc. President and CFO Christine Mikail Cvijic reported open-market sales of 4,800 shares of common stock under a pre-arranged Rule 10b5-1 trading plan. The sales occurred on two days at weighted average prices around the mid-$36 range.
After these transactions, she reports ownership of 84,040 shares, which includes 10,635 restricted stock units scheduled to vest on March 13, 2027, 13,533 restricted stock units vesting in equal installments on March 26, 2027 and March 26, 2028, and 22,000 restricted stock units vesting annually from February 20, 2027 through February 20, 2029. The filing notes that following completion of these sales she no longer holds any shares jointly with her spouse.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 4,800 shares ($173,375)
Net Sell
2 txns
Insider
Cvijic Christine Mikail
Role
President and CFO
Sold
4,800 shs ($173K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 4,200 | $36.134 | $152K |
| Sale | Common Stock | 600 | $36.021 | $22K |
Holdings After Transaction:
Common Stock — 84,040 shares (Direct, null)
Footnotes (1)
- The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on August 18, 2025. Shares sold were held jointly by the reporting person and her spouse, David Cvijic. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.035, inclusive. The reporting person undertakes to provide Neurogene Inc. (the "Company"), any securityholder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 13,533 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Following completion of all sales reported on this Form 4, the reporting person no longer holds any shares jointly with her spouse. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.455, inclusive. The reporting person undertakes to provide the Company, any securityholder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Key Figures
Shares sold July 7, 2026: 4,200 shares
Shares sold July 6, 2026: 600 shares
Total shares sold: 4,800 shares
+5 more
8 metrics
Shares sold July 7, 2026
4,200 shares
Open-market sale of common stock at weighted average $36.134
Shares sold July 6, 2026
600 shares
Open-market sale of common stock at weighted average $36.021
Total shares sold
4,800 shares
Net open-market sales reported across both transactions
Shares owned after transactions
84,040 shares
Total beneficial ownership reported following all sales on this Form 4
RSUs vesting March 13, 2027
10,635 RSUs
Restricted stock units granted March 13, 2024 vesting on March 13, 2027
RSUs vesting March 26, 2027-2028
13,533 RSUs
Restricted stock units vesting in equal installments on March 26, 2027 and March 26, 2028
RSUs vesting 2027-2029
22,000 RSUs
Restricted stock units vesting annually on February 20, 2027, 2028 and 2029
10b5-1 plan adoption date
August 18, 2025
Date reporting person adopted the trading plan governing these sales
Key Terms
Rule 10b5-1 plan, restricted stock units, weighted average price, open-market sale, +1 more
5 terms
Rule 10b5-1 plan regulatory
"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on August 18, 2025."
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
restricted stock units financial
"Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 13,533 restricted stock units granted on March 26, 2025..."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
weighted average price financial
"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.035, inclusive."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
open-market sale financial
"transaction_action: "open-market sale" with transaction code "S" for common stock on July 6 and July 7, 2026."
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
beneficial ownership financial
"Following completion of all sales reported on this Form 4, the reporting person no longer holds any shares jointly with her spouse."
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
FAQ
What insider transactions did Neurogene (NGNE) report for Christine Mikail Cvijic?
Neurogene’s President and CFO, Christine Mikail Cvijic, reported selling a total of 4,800 shares of common stock in open-market transactions. The sales were executed over two days at weighted average prices in the mid-$36 range under a pre-arranged Rule 10b5-1 trading plan.
At what prices were the Neurogene (NGNE) insider sales by the CFO executed?
The reported insider sales were executed at weighted average prices of $36.134 and $36.021 per share. Footnotes explain these were composed of multiple trades in ranges from $36.00 up to $36.455 per share, with full breakdowns available upon request to the company or SEC staff.
Were the Neurogene (NGNE) insider sales by the CFO under a Rule 10b5-1 plan?
Yes. The filing states that all transactions on this Form 4 were effected under a Rule 10b5-1 trading plan adopted on August 18, 2025. Such plans pre-schedule trades, indicating the timing of these sales was determined in advance rather than decided opportunistically.
What restricted stock units does the Neurogene (NGNE) CFO hold and when do they vest?
The CFO’s holdings include 10,635 restricted stock units vesting March 13, 2027; 13,533 units vesting in equal installments on March 26, 2027 and March 26, 2028; and 22,000 units vesting annually on February 20, 2027, February 20, 2028, and February 20, 2029, subject to applicable conditions.